Randomized Trial of Orathecin and Gemcitabine Versus Placebo and Gemcitabine in Patients With Non-Resectable Pancreatic Cancer Who Have Not Already Received Chemotherapy.

Trial Profile

Randomized Trial of Orathecin and Gemcitabine Versus Placebo and Gemcitabine in Patients With Non-Resectable Pancreatic Cancer Who Have Not Already Received Chemotherapy.

Discontinued
Phase of Trial: Phase II/III

Latest Information Update: 22 Jan 2013

At a glance

  • Drugs Gemcitabine; Rubitecan
  • Indications Pancreatic cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 22 Jan 2013 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 20 Oct 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 13 Oct 2009 Company added in the association field and additional lead trial center identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top